Generic drugs don’t need lengthy clinical trials to support a submission seeking FDA approval. The regulator now proposes ending this testing requirement for biosimilars, products that reference complex biologic medicines.
The post FDA Proposes Dropping Clinical Trial Requirements to Bring Biosimilars to Market More Quickly appeared first on MedCity News.
